The promise of immune cell therapy for acute kidney injury

Research output: Contribution to journalArticle

Abstract

Acute kidney injury (AKI) often results from ischemia reperfusion, sepsis, or exposure to nephrotoxins and is associated with a high rate of mortality and morbidity. Advances in understanding the pathophysiology of AKI may lead to the development of specific therapies. Although there is evidence of an important role for immune cells in AKI, the specific relevant populations and the mechanisms of their actions are unclear. In this issue of the JCI, Li et al. demonstrate that adenosine manipulates DC responses to kidney injury, raising hope that immunotherapy could be a tangible approach to AKI.

Original languageEnglish (US)
Pages (from-to)3852-3854
Number of pages3
JournalJournal of Clinical Investigation
Volume122
Issue number11
DOIs
StatePublished - Nov 1 2012

Fingerprint

Cell- and Tissue-Based Therapy
Acute Kidney Injury
Adenosine
Immunotherapy
Reperfusion
Sepsis
Ischemia
Morbidity
Kidney
Mortality
Wounds and Injuries
Population
Therapeutics

ASJC Scopus subject areas

  • Medicine(all)

Cite this

The promise of immune cell therapy for acute kidney injury. / Rabb, Hamid.

In: Journal of Clinical Investigation, Vol. 122, No. 11, 01.11.2012, p. 3852-3854.

Research output: Contribution to journalArticle

@article{3dff10ba016341dfb730bec484074075,
title = "The promise of immune cell therapy for acute kidney injury",
abstract = "Acute kidney injury (AKI) often results from ischemia reperfusion, sepsis, or exposure to nephrotoxins and is associated with a high rate of mortality and morbidity. Advances in understanding the pathophysiology of AKI may lead to the development of specific therapies. Although there is evidence of an important role for immune cells in AKI, the specific relevant populations and the mechanisms of their actions are unclear. In this issue of the JCI, Li et al. demonstrate that adenosine manipulates DC responses to kidney injury, raising hope that immunotherapy could be a tangible approach to AKI.",
author = "Hamid Rabb",
year = "2012",
month = "11",
day = "1",
doi = "10.1172/JCI66455",
language = "English (US)",
volume = "122",
pages = "3852--3854",
journal = "Journal of Clinical Investigation",
issn = "0021-9738",
publisher = "The American Society for Clinical Investigation",
number = "11",

}

TY - JOUR

T1 - The promise of immune cell therapy for acute kidney injury

AU - Rabb, Hamid

PY - 2012/11/1

Y1 - 2012/11/1

N2 - Acute kidney injury (AKI) often results from ischemia reperfusion, sepsis, or exposure to nephrotoxins and is associated with a high rate of mortality and morbidity. Advances in understanding the pathophysiology of AKI may lead to the development of specific therapies. Although there is evidence of an important role for immune cells in AKI, the specific relevant populations and the mechanisms of their actions are unclear. In this issue of the JCI, Li et al. demonstrate that adenosine manipulates DC responses to kidney injury, raising hope that immunotherapy could be a tangible approach to AKI.

AB - Acute kidney injury (AKI) often results from ischemia reperfusion, sepsis, or exposure to nephrotoxins and is associated with a high rate of mortality and morbidity. Advances in understanding the pathophysiology of AKI may lead to the development of specific therapies. Although there is evidence of an important role for immune cells in AKI, the specific relevant populations and the mechanisms of their actions are unclear. In this issue of the JCI, Li et al. demonstrate that adenosine manipulates DC responses to kidney injury, raising hope that immunotherapy could be a tangible approach to AKI.

UR - http://www.scopus.com/inward/record.url?scp=84868629885&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84868629885&partnerID=8YFLogxK

U2 - 10.1172/JCI66455

DO - 10.1172/JCI66455

M3 - Article

C2 - 23093787

AN - SCOPUS:84868629885

VL - 122

SP - 3852

EP - 3854

JO - Journal of Clinical Investigation

JF - Journal of Clinical Investigation

SN - 0021-9738

IS - 11

ER -